About · [Company name]

Two decades of recombinant protein science — now cosmetic grade.

[Company name] has produced and characterized recombinant proteins since 2004, as one of the early companies offering commercial molecular biology services. We now bring that same manufacturing and quality standard to cosmetic-grade growth factors and peptides.

Est. 2004·20+ years in recombinant proteins·30+ specialists (PhD-level)·100+ developments·Peer-reviewed & patented

[ figures to verify — exact numbers pending confirmation ]

Who we are

For two decades our work has centered on recombinant proteins — from molecular design and expression producer strains to peptide synthesis and preparative purification — for research, diagnostics and pharmaceutical use.

The same scientific and manufacturing foundation now underpins our cosmetic-grade growth factors and peptides: the molecules are different, the standard of production and characterization is not.

We are a manufacturer, not a reseller. Every active is designed, expressed, purified and released in-house — which is why we can ship free evaluation samples with a batch-specific Certificate of Analysis.

Capabilities (in-house)

Molecular design of recombinant proteins
Expression producer strain development
Fermentation & recombinant protein production
Peptide synthesis
Preparative purification
Analytics & quality control
photo: fermentation
photo: chromatography
photo: QC lab

Peer-reviewed research

Our team's work in recombinant protein design, strain development and characterization is published in peer-reviewed journals.

  1. 01Development of Shortened Recombinant Flagellin and Study of Its Radioprotective Efficacy in MiceBiology Bulletin · 2025
  2. 02Safety and specific activity of the recombinant SARS-CoV-2 allergen ("CoronaDerm-PS"), phase I–II clinical trialsRussian Journal of Infection and Immunity · 2024
  3. 03Purification technology and biochemical/immunological characterization of a recombinant chimeric antigenMedical Immunology · 2024
  4. 04Development of an E. coli producer strain for a SARS-CoV-2 N/S/M/E antigenRussian Journal of Infection and Immunity · 2022
  5. 05DNA immunogen based on SARS-CoV-2 genesProceedings of VSUET · 2023

Full publication list and patents available on request.

Team

30+ specialists in genetics, biochemistry, microbiology and biotechnology, including holders of Doctor of Science and Candidate of Science degrees, with experience across both research and production.

[ photo ]
Head of R&D
[ name ]
[ credentials ]
[ photo ]
Head of QC
[ name ]
[ credentials ]

Every batch is characterized and released with a Certificate of Analysis. We encourage independent verification, and we ship free evaluation samples so customers can test each active in their own lab.

See our quality process →

Company & contacts

Legal entity
[ Legal entity ]
Address
[ Address ]
Email
[ Email ]
Phone
[ Phone ]
[ map — optional ]

Request material and specifications for your formulation.